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Abstract: Possible sources of variation in non-polar secondary metabolites of Portieria 
hornemannii, sampled from two distinct regions in the Philippines (Batanes and Visayas), 
resulting from different life-history stages, presence of cryptic species, and/or spatiotemporal 
factors,  were investigated. PCA analyses demonstrated secondary metabolite variation 
between, as well as within, five cryptic Batanes species. Intraspecific variation was even 
more pronounced in the three cryptic Visayas species, which included samples from six 
sites. Neither species groupings, nor spatial or temporal based patterns, were observed in 
the PCA analysis, however, intraspecific variation in secondary metabolites was detected 
between life-history stages. Male gametophytes (102 metabolites detected) were strongly 
discriminated from the two other stages, whilst female gametophyte (202 metabolites 
detected) and tetrasporophyte (106 metabolites detected) samples were partially 
discriminated. These results suggest that life-history driven variations, and possibly other 
microscale factors, may influence the variation within Portieria species. 
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1. Introduction  
Natural products, and in particular secondary metabolites, have been the focus of study in many 
marine macroalgae. Seaweeds interact with their environment utilizing a rich variety of secondary 
metabolites [1–4]. These chemical compounds have no explicit role in the internal metabolism of the 
organisms [1,5,6] but serve as defense mechanisms against grazers, competitors, fouling organisms 
and pathogens [7–9]. The compounds are localized in specialized cells, have relatively low molecular 
weights (<3000 Daltons), are structurally diverse, often halogenated, and exist in low abundance (often 
<1% of total carbon) [1,2,6,10–12].  
Secondary metabolites have drawn wide attention because of their pharmaceutical potentials, 
chemotaxonomic and ecological importance [13–16]. Macroalgae produce a wide range of compounds 
such as terpenes, phenols, fatty acids, lipopeptides, amides, alkaloids, terpenoids, lactones, pyrroles 
and steroids [9,15,17]. Red seaweeds belonging to the family Rhizophyllidaceae have been found to be 
especially rich in secondary metabolites, harboring a variety of halogenated monoterpenes. The 
tropical, Indo-Pacific genus Portieria (synonyms Chondrococcus and Desmia), is a prolific source of 
these halogenated compounds [11,12,18–24], about 80 of which have been isolated (Table S1). Among 
the most interesting of these compounds is halomon, a monoterpene with anti-tumor properties, 
isolated from samples collected in Batanes, Philippines [22,23]. However, the inconsistent availability 
of this compound from natural populations prevented further drug development.  
Previous studies have mainly focused on discovery and pharmaceutical potentials of chemical 
compounds in P. hornemannii. Only a few studies have addressed inter- or intraspecific variation in 
secondary metabolite composition. Puglisi and Paul [25] tested the carbon/nutrient hypothesis, which 
postulates that the secondary metabolites produced by a certain alga are dependent on the nutrient 
availability.  They found that variation of ochtodene concentrations in P. hornemannii  cannot be 
attributed to nitrogen and phosphorus availability but suggested instead that light was a contributing 
factor. Matlock et al. [24] demonstrated strong site-to-site differences, variation within populations, 
and limited evidence for temporal variation in apakaochtodene levels. Some authors have emphasized 
the necessity to genotype the organisms in order to better understand the mechanisms that regulate the 
production of specific natural products [5,26–28].We found evidence for a large number of cryptic 
species within Portieria in the Philippines [29], but the effect of intraspecific genetic variation in 
relation to secondary metabolites has not been tested to date. 
This study aims to understand if non-polar secondary metabolites of Portieria  plants vary 
quantitatively or qualitatively between cryptic species and among life stage within species. We employed 
metabolite fingerprinting and multivariate analyses of chromatograms of extracts of samples collected 
in the Philippines. The large number of compounds produced by Portieria, the lack of commercial 
standards and the scarcity of compound identification resources (mass spectral databases) dedicated to 
marine secondary metabolites makes metabolite fingerprinting the most feasible analytical method to 
define variation between cryptic species and among life-history stages within species. In contrast to 
target analysis, metabolite fingerprinting does not separate individual metabolites, but instead compares 
spectra of whole extracts using multivariate statistics [30]. Metabolite fingerprinting is particularly 
useful for rapid classification of samples [31]. Our specific aims were to evaluate: (1) if there is 
variation of non-polar secondary metabolites between the gametophyte and tetrasporophyte life-history Mar. Drugs 2011, 9                       
 
 
2440 
stages of Portieria, (2) if metabolite variation is due to the presence of phylogenetically distinct cryptic 
species, and (3) if patterns of variation are observed on a geographical and temporal level. 
2. Results and Discussion  
2.1. Cryptic Diversity 
Phylogenetic analyses of 152 cox2-3 sequences revealed 12 clades of closely related sequences, 
preceded by long well-supported branches. Seven lineages include specimens from Batanes and five 
clades are restricted to the Visayas (Figure 1). These clades will further be regarded as species. Details 
on cryptic diversity and species delimitation are reported in Payo [29]. 
Figure 1.  Phylogenetic tree reconstructed using Bayesian inference based on the 
mitochondrial  cox2-3  spacer  of  Portieria  specimens collected from Batanes (B) and 
Visayas (V) Islands in the Philippines. Branch support (posterior probabilities) ≥ 0.5 are 
indicated at the branches. The eleven clades represent cryptic lineages, likely equivalent to 
species. Species B34 and B38 were not included in the chemical analysis. 
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2.2. Identification of Compounds in Non-Polar Extracts 
Owing to the lack of standard compounds and public repositories of mass spectral data specific to 
marine metabolites, the identity of the compounds was investigated only by comparing the mass 
spectra and the Kovats retention indices to those deposited in publicly available databases (MassBase, 
Pherobase, Lucero Library and the free limited NIST database in the MS Search Program and 
AMDIS). Identifications were based on a minimum of 80% similarity of mass fragments. Using a 
retention  index  calculator  [32], plant volatiles with the nearest Kovats Index (KI) to that of the 
compounds in the samples were retrieved. The KI used for compound identification is based on a DB5 
capillary column similar to the non-polar, low bleed HP-5MS column used for GC/MS in this study. 
The Lucero KI based identification was verified with the mass spectra and KIs listed in Pherobase. 
Comparison with mass spectra of compounds found in Portieria in the literature [11,12,33] did not 
reveal any positive identification. Examination of mass fragments did not show any similarity of 
components with that of halomon’s mass spectral fragments as reported by Egorin et al. [33]. 
2.3. Metabolite Fingerprinting 
2.3.1. Variation Between Life Stages 
Plants used for this study belonged to a single species V1B (Figure 1) and were collected on the 
same day from a single site in Bantayan, Dumaguete. A total of 202 non-polar compounds were 
detected from gametophytes and tetrasporophyte samples by GC-MS (Table S2). Using an external 
standard and the databases, the first peak of each sample (RT = 6.18 min) was confirmed as   
β–myrcene (Figure 2a). Of the remaining compounds, only 11% (22) were identified using NIST and 
MassBase. Based on the NIST and MassBase identifications, five compounds were monoterpenes. 
Examination of the patterns of parent ions showed ten halogenated compounds containing one Cl or 
one Br. Two hundred compounds had a KI ranging 993–1969. Some peaks with succeeding retention 
times shared the same KI but had a different mass spectra composition. NIST and MassBase did not 
share the same identification of peaks except for β-myrcene. 
KI for the last two peaks were not computed since it occurred later than the last alkane standard 
(C20 at 31.226 min) that was used for KI calculation. We also explored the potential of the Lucero 
library and Pherobase to identify compounds that Portieria might have in common with land plants. 
The Lucero library retrieved the nearest KIs of plant volatiles. Some of these identifications were 
verified at Pherobase, but mass spectra composition of the unidentified peaks was not similar to the 
spectra of the compound name retrieved from the database. Furthermore, we also tried to retrieve 
compounds with a certain KI and examined the corresponding spectra. β-Myrcene has a KI of 993.543 
in this study. Pherobase listed 991 and 994 as KIs for β-myrcene in a DB5 column. Nine compounds 
listed in the database have a KI of 993. 
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Figure 2. Portion of GC-MS total ion chromatograms of non-polar extracts of Portieria 
samples:  (a)  male gametophyte from Bantayan (Dumaguete),  V1;  (b) White  Beach, 
Batanes, B21; (c) Liloan, V32. β-myrcene, a precursor of many halogenated monoterpenes, 
was detected only in the Bantayan specimens. Naphthalene is used as an internal standard. 
 
Figure 3.  Frequency distribution indicating number of shared and unique non-polar 
secondary metabolites: (a) within life-history stage of species V1B from Bantayan, female 
(F), male (M) and tetrasporophyte (T); (b) among sites of species V32 collected in Sawang 
(SAW), Liloan (LIL) and Pagubagubaan (PAG). 
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The Lucero library lists KI 993 for β-myrcene. With the large number of metabolites retrieved, this 
method of verification proved cumbersome especially since Pherobase currently does not allow 
automated mass spectral and KI comparison. Of the 202 compounds detected, 155 compounds were 
present  in the female samples, 102 in male plants and 106 in tetrasporophytes (Figure 3a).  
There were 55 compounds that were shared by all life stages. Sixty-three compounds were found 
exclusively in female gametophyte extracts, 15 in male gametophyte extracts, and 18 in tetrasporophyte 
extracts. There were 14 compounds common to male and tetrasporophyte extracts. The male and 
female gametophyte shared 18 compounds while female and tetrasporophyte shared 19 compounds.  
A precursor compound of the monoterpenes, myrcene, was detected in all of the life stages but not in 
all replicates. 
Figure 4.  Principal  component  analysis of GC-MS standardized relative abundance 
datasets which includes the compounds detected in a 67-min run of Portieria extracts.  
(a) Male gametophyte (M1-2) samples are clearly discriminated occurring at the positive 
end of the plane while female gametophyte (F2-7) and tetrasporophyte samples (T1-2) are 
only partially discriminated by Factor 1; (b) Batanes dataset includes five cryptic species. 
The  clustering of B35 replicates and the scattered pattern of B5 suggest variation in 
component compounds exists between species but at the same time suggested that variation 
within species can occur. 
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We applied a principal component analysis (PCA) on the standardized relative abundances to 
determine if metabolites differ among life stages (Figure 4a). The matrix contained 202 compounds 
(active variables) and ten samples (active cases: six female gametophytes, two male gametophytes, and 
two tetrasporophytes). All samples were collected on the same day from a single site, and belong to a 
single species. Figure 4a shows the projection of the cases on the factor plane. Factor 1 and factor 2 
accounts for 20.42% and 14.37% of the variation, respectively. Factor 1 clearly discriminated the male 
gametophytes from the others, whilst the female gametophytes and tetrasporophytes, although 
separated, were more closely aligned. Factor 2 does not discriminate between life stages but points 
towards additional variation within life stages. 
2.3.2. Variation Between Cryptic Species 
A total of 67 compounds were detected from nine samples (three technical replicates) by GC-MS 
(Table S3). These samples belonged to the five species B8, B5, B21, B33 and B35, as determined by 
DNA sequence analysis. A sample consists of pooled extract of eight individuals belonging to one 
species as verified by DNA analysis. β-Myrcene was not detected in any of the samples (Figure 2b). 
Unfortunately the three databases used (NIST, MassBase, Lucero library) did not give identical 
identifications of compounds.  NIST identified  four  compounds appearing at different times as   
2,2-dimethyl-3-hexanone. Comparison of mass spectra with MassBase resulted in the retrieval of 
straight and branched alkanes and alkenes. Compounds with retention times from 8.11 to 30.69 min 
had retention indices from 1065 to 1965. No KIs were computed for the rest of the compounds. 
Comparison of computed KIs with those in the Lucero library indicated compounds from these 
samples contained monoterpenes, sesquiterpenes, esters, fatty acids and alcohols. NIST, MassBase and 
the Lucero databases did not share the same identification of compounds. Visual examination of parent 
ions showed only two compounds to be halogenated containing either one Cl or one Br. 
Table 1. Frequency of compounds that are unique to or common to several species of 
Portieria found in Batanes. Values in parenthesis indicate total number of compounds 
found in a species, while 1 indicates presence and 0 absence of a compound. 
B21 (49)  B33 (51)  B35 (60)  B8 (57)  B5 (57)  Frequency (67) 
0  0  0  1  0  1 
0  0  1  1  0  3 
0  0  1  1  1  3 
0  1  0  0  0  1 
0  1  0  1  0  2 
0  1  1  1  0  1 
0  1  1  1  1  7 
1  0  1  0  1  3 
1  0  1  1  0  2 
1  0  1  1  1  4 
1  1  0  0  1  2 
1  1  0  1  1  1 
1  1  1  0  1  4 
1  1  1  1  1  33 Mar. Drugs 2011, 9                       
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The number of compounds detected varied between the five species (Table 1) and among biological 
replicates. Species B35 had the highest number of compounds detected (60/67), species B33 contained 
51/67 compounds detected, species B8 and B5 both had 57/67 compounds detected and species B21 
had the least number of compounds (49/67). There were 21 compounds that were detected in all nine 
samples, while 33 compounds were present in all five species. 
To detect distinct groupings, we conducted a PCA based on the standardized relative abundances of 
the nine samples using the 67 compounds as variables (Figure 4b). The first principal axis accounted 
for 27.4% of the variance while the second 16.0%. Plotted scores from the PCA did not show distinct 
interspecific clusters. The largest variation was displayed by specimens belonging to species B5. 
2.3.3. Spatial and Temporal Variation 
Six sites in the Visayas (Sawang, Pagubagubaan, Dapdap, Siaton, Liloan and Bantayan (Dumaguete); 
n  = 44) were sampled from 2007 to 2009 and investigated using Spectconnect to determine if 
seasonality or geography explained the variation in secondary metabolites. A total of 33 compounds 
were detected from these samples (Table S4), however, β-myrcene was not detected (Figure 2c). As in 
previous datasets, the three databases (NIST, MassBase, Lucero library) used did not give identical 
identifications of compounds. Comparison of mass spectra with MassBase resulted in the retrieval of 
eleven compounds, most likely straight and branched alkanes and alkenes. Many of the peaks detected 
eluted later than the standard, icosane (C20), hence were not included. Comparison of computed RIs 
with those in Lucero library retrieved the following compound classes: monoterpenes, sesquiterpenes, 
esters and fatty acids. NIST library identified two compounds, 3-hexanone, 2,2-dimethyl- and disilane. 
No halogenated compounds were detected. 
Figure 5.  Principal component analysis of GC-MS standardized relative abundance 
datasets for detecting possible spatial and temporal patterns in: (a) the Visayas species; 
(b) the Visayas samples belonging to species V32. Letters indicate sampling site (DAP: 
Dapdap; PAG: Pagubagubaan; SAW: Sawang; SIA: Siaton) and numbers indicate month 
and year of sampling. 
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Figure 5. Cont. 
 
PCA was conducted using the standardized relative abundance file generated by Spectconnect   
(n = 44) using the 33 compounds as variables (Figure 5a). The first and second PCs accounted for 
17.87% and 17.78% of the variance, respectively. No clear groupings could be deduced based on 
species, sampling period, or sampling site. Most of the samples clumped except for one Siaton and two 
Bantayan samples, which were clearly separated from the rest. A PCA excluding these three samples 
slightly spread the rest of the samples but likewise did not show any recognizable clusters (Figure 5a). A 
separate PCA analysis was conducted on samples belonging to the same species, V32, from Sawang, 
Pagubagubaan, and Liloan (Figure 5b). The first and second PCs accounted for 21.36% and 14.96% of 
the variance, respectively. Again, no clusters based on site or period of collection were detected. 
2.4. Patterns of Secondary Metabolite Distribution 
Distribution of secondary metabolites in marine macroalgae exhibit macroscale and microscale 
patterns [34]. Macroscale patterns include global patterns within or across algal taxa, patterns within a 
specific habitat, and patterns correlated with biotic and abiotic factors. Microscale patterns are related 
to molecular and biochemical processes within an algal thallus, the spatial distribution of compounds 
within an algal thallus and temporal responses (short- and long-term responses). In Portieria neither 
macro- nor microscale patterns of secondary metabolite variation have been fully explored.  
Although three decades of studies have been dedicated to the isolation of new compounds only two 
have investigated the variation of these, specifically ochtodene and apakaochtodene A and B [24,25]. 
However, a possible drawback related to these studies is the fact that individual compounds are not 
mutually independent but are linked via biological pathways as is the case for β-myrcene, which is the 
likely precursor of many monoterpenes [35], and whose presence influences the presence or absence of 
other halogenated monoterpene components. Hence in order to understand general or specific 
metabolite patterns, knowledge of the presence and absence of progenitor compounds is essential. The 
present study has successfully described the variation of the non-polar secondary metabolites of 
Portieria on a macroscale level using metabolite fingerprinting. Mar. Drugs 2011, 9                       
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Reports on intraspecific variation of secondary metabolites in macroalgae have been based on 
variations within individuals, between individuals of a population and among geographically isolated 
populations [36,37]. Our results suggest substantial intraspecific variation among the life-history 
stages of Portieria. Male gametophytes form a clearly distinct group, while a partial discrimination 
was detected between female gametophytes and tetrasporophytes (Figure 4a). Furthermore, our results 
show that female gametophytes are chemically richer in terms of the number of secondary metabolites 
(Figure 3a), possibly providing protection to the carposporophyte from grazers. Many of the 
compounds detected appear to occur exclusively to a certain life-history stage while a relatively small 
group of compounds is shared among life-history stages. Similarly, male gametophytes of 
Asparagopsis armata were found to have lower concentration of the secondary metabolite bromoform 
compared to female gametophytes [37]. It has also been observed that the carposporophyte phase of A. 
armata was the least consumed life-history phase by the seahare, Aplysia parvula [37]. Likewise, in 
the brown alga Dictyota menstrualis, female gametophytes were found to produce more diterpenes 
compared to the other life-history stages [38]. 
Comparative analyses of the five cryptic species from Batanes (B5, B21, B33, B35, and B8) 
showed variation between, as well as within species (Figure 4b). Intraspecific variation is even more 
pronounced in the Visayas dataset (Figure 5). Neither species specific nor spatio-temporal patterns 
were evident. 
In addition, a separate PCA including only specimens of species V32 (Figure 3b) did not elucidate 
patterns based on collection site or period. The results suggest that life history related variations 
combined with microscale factors have a large influence on the variation within Portieria species. 
Pelletreau and Targett [34] pointed out that the existence of inducible and activated defenses 
complicates the search for universal patterns of secondary metabolites and continues to highlight the 
importance of localized phenomena. We conducted a preliminary grazing experiment in  outdoor  
flow-through aquaria to assess the influence of the herbivore (Aplysia) on the production of 
metabolites in Portieria. However, these efforts were beset by two factors: death of plants due to high 
water temperature and continuous development of microscopic Aplysia larvae on field collected plants 
undergoing acclimatization. Future grazing experiments will attempt to eliminate these  factors. In 
addition more extensive sampling should confirm the patterns observed during the present study. 
Finally, there was difficulty in achieving unequivocal identification of compounds in this study 
unveiling the need for mass spectral and KI databases dedicated solely to marine secondary 
metabolites. Such repositories will assist in the identification of previously reported compounds for 
investigations mainly focused on rapid detection and understanding of chemical patterns in marine 
organisms. In doing so, future studies will not just be focused in isolating and naming novel 
compounds as had been the trend in Portieria but will also seek to answer questions of biological or 
ecological relevance. Furthermore, the presence of cryptic species in Portieria highlights the need to 
genotype organisms ensuring that correct species identification is correlated with metabolite fingerprint, 
enabling more targeted approaches in future studies. 
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3. Experimental Section  
3.1. Collection and Storage 
Field samplings were performed at different periods from several sites in the Philippines (Figure S1). 
Plants were collected by snorkeling and SCUBA, diving depths ranging from 1–20 m. For secondary 
metabolite characterization of the different life-history stages of Portieria, plants were collected 
randomly from Bantayan near Dumaguete (Figure S1c) on December 29, 2009. To allow both chemical 
characterization and life-history stage verification plants were blotted dry and stored over silica. 
Plants for secondary metabolites analysis between species were collected from four sites in Batanes 
(Basco, White Beach, Coral, and in Chavayan) (Figure S1a,b) on April 23–26, 2009. Plants were 
preserved in 95% ethanol in the field and stored at −23 °C afterwards. Sampling for seasonal and 
spatial comparison of secondary metabolites were conducted from six sites in the Central Visayas 
(Dapdap, Siquijor, Siquijor; Pagubagubaan, San Juan, Siquijor; Sawang, San Juan Siquijor; Bantayan, 
Dumaguete, Negros Oriental; Siaton, Negros Oriental; Liloan, Santander, Cebu (Figure S1a,c) from 
2007 to 2009. For the first four sites, plants were collected on a monthly basis when present and when 
abundant enough to afford a good amount for extraction. For sites close to the Silliman Marine 
Laboratory, plants were immediately packed and stored at −23 °C upon arrival. When immediate 
freezing was not possible, plants were preserved in 95% ethanol in the field and stored at −23 °C. 
Frozen plants were rinsed in freshwater or in ethanol and blotted dry. 
As Portieria cannot be distinguished morphologically, species identification was based on DNA 
sequence data (see below). For DNA characterization, thallus clippings were collected from specimens 
and stored in silica while in the field. 
3.2. Extraction 
3.2.1. Life-History Stages Comparison 
Portieria has a tri-phasic isomorphic life history which includes free-living haploid male and female 
gametophytes, a diploid carposporophyte attached to and dependent on the female gametophyte, and a 
free-living diploid tetrasporophyte. Silica-dried specimens were examined under the microscope and 
segregated into different life-history stages (male gametophytes, female gametophytes, and 
tetrasporophytes). Biological replicates, each about 1 gram dry weight, were prepared for every   
life-history stage. Tissues were ground using mortar and pestle, dissolved in 6 mL dichloromethane 
(DCM) containing 50 µg·mL
−1 naphthalene, and vortexed for a few seconds. The DCM extracts were 
allowed to stand at room temperature for 24 h in screw-cap tubes. The extracts were decanted and 
transferred to air tight screw-cap tubes and stored at −23 °C. The tissues were steeped in DCM for 
another 24 h. First and second extracts of a sample were pooled and filtered using Whatman GF/C. 
The combined extracts were loaded onto pre-conditioned SPE tubes containing 10 g of silica (Silicycle 
SiliaFlash
® G60, 60–200 μm, 60 Å). Non-polar compounds were eluted using 12 mL hexane. The 
eluate was concentrated to 0.5 mL under N2 gas. Three 100 µL replicates were taken from this stock 
and used as technical replicates in the GC-MS analysis.  
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3.2.2. Species Comparison 
The samples were extracted individually. Tissue was ground using a mortar and pestle and extracted 
twice in 6 mL DCM overnight. Extracts were pooled, loaded onto 2 g silica and eluted using 6 mL of 
hexane. Eluates of eight samples belonging to the same species, approximately weighing 10–26 g, 
were pooled and evaporated down to 100 µL. To assess consistency in the GC-MS analyses, three 
technical replicates were prepared for each sample.  
HPLC solvents for extraction and chromatography (DCM and n-hexane) were sourced from 
Mallinckrodt or HiperSolv Chromanorm). Naphthalene (Fisher) and β-myrcene (Sigma) were used as 
internal and external standards, respectively. 
3.2.3. Seasonal and Spatial Comparison 
For seasonal analysis, plant material was ground using mortar and pestle. Twenty grams of ground 
material was extracted in 20 mL DCM for 24 h at room temperature. The material was extracted a 
second time in 20 mL DCM and the extracts were pooled. To measure the amount of green oil that was 
generated, one of the two pooled extracts was evaporated to dryness using nitrogen. The oil was 
weighed and redissolved in 20 mL DCM. The other extract was evaporated down to 20 mL. Both 
extracts were loaded in SPE columns containing 10 g of silica (Silicycle SiliaFlash
® G60, 60–200 μm, 
60 Å). Non-polar compounds were eluted from the column with 20 mL hexane and again reduced to 
100 µL. A separate aliquot of ground plant tissue was used to determine dry mass. 
3.3. Phylogenetic Analysis 
Assignment of the sampled specimens to cryptic species was based on phylogenetic analysis of the 
mitochondrial  cox2-3 spacer region. The phylogeny includes specimens collected from  five  sites 
(Basco, Chanaryan, Coral, Mahatao, Chavayan) in Batanes and six sites (Dapdap, Siquijor; Sawang, 
San Juan, Siquijor; Pagubagubaan, San Juan, Siquijor; Malo, Siaton; Bantayan, Dumaguete;   
Liloan, Santander) in the Visayas, Philippines. Species delineation follows the rational outlined in  
Payo  et al.  [29]. DNA extraction, PCR amplification, sequencing and sequence alignment were 
performed as described in Payo et al. [29].The alignment of 152 Portieria sequences was 345 bp long. 
Bayesian inference (BI) of phylogeny was performed using MrBayes v3.1.2 [39] under a GTR + I + Γ 
model as determined by jModelTest [40]. BI analyses consisted of two parallel runs of three 
incrementally heated chains and one cold chain each, and 3 million generations with sampling every 
1000 generations. A burnin value of 750 was determined using TRACER V1.4 [41]. 
3.4. Metabolite Analysis, Data Processing and Multivariate Analysis 
3.4.1. GC-MS Analysis 
GC-MS analyses of the non-polar eluates were performed using an Agilent 6890 gas chromatograph 
and Agilent 6973 mass selective detector. Sample injection volume was 1 μL. Split injection with a 
split ratio of 20:1 was used. The carrier gas was helium with a total flow rate of 72.7 mL·min
−1 and 
26.20 psi column head pressure. Compounds were separated using a 30 m × 0.25 mm HP-5 MS  Mar. Drugs 2011, 9                       
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non-polar capillary column (Hewlett-Packard, 5% phenyl methyl siloxane, 0.25 μm thickness) for a 
run time of 67 min. under the following oven temperature program: 50 °C initial held for 2 min, then 
increased at a rate of 5  °C·min
−1  to 300 °C, held for 15 min. The spectrometers were run in   
electron-impact mode with ionization energy of 70 eV and an ion source temperature ranging 230–250 °C. 
The scan range was set to detect masses 50–500 amu. 
3.4.2. GC-MS Data Processing 
The software AMDIS [42] was used for peak identification and deconvolution of the 
chromatogram. This method calculates and retrieves pure (background-free) mass spectra from raw 
GC-MS data files based from the parameters indicated by the user. The following parameters were 
used for all of the analyses: medium shape requirement, medium sensitivity, and medium resolution. 
The ELU files generated from AMDIS were submitted for analysis using Spectconnect [43] to generate 
matrices of component peaks (relative abundance, retention time, integrated signal and base peak). 
3.4.3. Compound Identification 
In the absence of pure standards of compounds previously isolated from Portieria  (except for   
β-myrcene), we used KI’s, freely available mass spectral databases to determine identity of component 
peaks, and literature. We computed the Kovat’s or retention index of each peak using the retention 
times of alkane standards C8–C20 and the Retention Index Calculator [32]. The retention index is 
derived from the interpolation (usually logarithmic), relating the adjusted retention volume (time) of 
the sample component to the adjusted retention volumes (times) of two standards eluted before and 
after the peak of a sample component (IUPAC definition). The calculated KI was automatically 
compared to the KI’s of compounds stored in the built-in library of the calculator. Mass spectra of 
component peaks were compared to compounds retrieved from MassBank [44], Pherobase [45] and the 
limited version of the NIST library in the MS Search Program and AMDIS. Mass spectra of 
components were inspected for similarity with those of the characteristic mass signals of components 
published in [11,12,33]. 
3.4.4. Data Standardization, Metabolite Fingerprinting and Multivariate Analyses 
Relative abundance matrices generated from the Spectconnect analyses were used for statistical 
analyses. A matrix contains relative abundance values of all detected components across all samples 
included in the analysis. The data were standardized by obtaining a ratio between the relative 
abundance of a component per replicate (or sample) and the total of all components per replicate (or 
sample). The ratios obtained among the technical replicates were subsequently averaged. Principal 
component analysis was performed using Statistica 7.0 (StatSoft Inc., Tulsa, OK, USA) on each 
dataset to detect any pattern or groupings based from the variables which are the component compounds. 
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4. Conclusions  
Portieria species in the Philippines are a rich source of secondary metabolites. This diversity in 
secondary metabolites amounts to at least 302 various compounds. The majority of which are exotic, 
remain undescribed and therefore are not available in natural product databases. Our study demonstrates 
that metabolic fingerprinting presents a practical approach to disclose intra- and interspecific patterns 
of secondary metabolites. Variation in secondary metabolites occurs between,  as well as within, 
Portieria  species.  Preliminary results, based on a relatively small sample size,  demonstrate that 
extensive intraspecific variation in secondary metabolites occurs between life-history stages. Female 
gametophytes (202 compounds) are chemically richer compared to that of the males (102) and 
tetrasporophytes (106). No spatio-temporal patterns were evident among the datasets. These results 
suggest that life-history driven variations and possibly other microscale factors may have an important 
influence on the variation of secondary metabolites within Portieria species. More exhaustive sampling 
is needed to confirm the life-stage specific metabolic fingerprints. In addition, to determine whether 
the  intraspecific variation of the analyzed part of non-polar metabolome remains lower than the 
interspecific variation, it will be necessary to expand the taxon sampling across different cryptic species. 
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Supplementary 
Table S1. List of compounds isolated from Portieria (syn. Desmia and Chondrococcus) 
hornemannii, based on previous studies. 
Reference  Cpd #  Name  Mol. Formula  Description  Specimen Source 
[18]  1  Myrcene  C10H16  acyclic 
halogenated 
monoterpene 
Amami Is., Japan 
  2  7-chloro-myrcene  C10H15Cl  "  " 
  3  7-bromo-myrcene  C10H15Br  "  " 
  4  (Z)-10-bromo-myrcene  C10H15Br  "  " 
  5  (E)-10-bromo-myrcene  C10H15Br  "  " 
  6  (Z)-10-bromo-7-chloro-
myrcene 
C10H14BrCl  "  " 
  7  (E)-10-bromo-7-
chloro-myrcene 
C10H14BrCl  "  " Mar. Drugs 2011, 9                       
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  8  3-chloro-7, (Z)-10-
dibromo-myrcene 
C10H13Br2Cl  "  " 
  9  (Z)-10-chloro-3,7-
dibromo-myrcene 
C10H13Br2Cl  "  " 
  10  3-bromo-7-chloro-
myrcene 
C10H14BrCl  "  " 
  11  7-bromo-10-chloro-
myrcene 
C10H14BrCl  "  " 
  12  -  C10H15Br  cyclic halogenated 
monoterpene 
" 
[19]  1  chondrocole A  C10H14BrClO  "  Hawaii 
  2  chondrocole B  C10H14BrClO  "  Hawaii 
[46]  3  -  C10H15Cl3Br2  acyclic 
halogenated 
monoterpene 
Black Point, 
Oahu, Hawaii 
  4  -  C10H16Cl3Br  "  " 
  5  -  C10H15Cl2Br  "  " 
  6  -  C10H16Cl2Br2  "  Halona Blowhole 
Is, Oahu, Hawaii 
  10  -  C10H16Cl2Br2  acyclic 
halogenated 
monoterpene 
" 
  11  6-bromo-2-
chloromyrcene 
C10H15ClBr  "  Black Point, 
Oahu, Hawaii 
  12  chondrocole c  C10H14Br2O    cyclic halogenated 
monoterpene 
" 
  13  -  C10H15Cl3Br2  acyclic 
halogenated 
monoterpene 
Hawaii 
  14  Z-3-bromomethylene-
7-methyl-1,6-octadiene 
C10H16ClBr2  "  Halona Blowhole 
Is., Oahu, Hawaii 
  15  -  C10H14Br2Cl2  cyclic halogenated 
monoterpene 
" 
[47]  1  myrcene  C10H16  acyclic 
halogenated 
monoterpene 
Kada Coast, 
Wakayama Pref., 
Japan 
  2  7-chloro-myrcene  C10H15Cl  "  " 
  3  7-bromo-myrcene  C10H15Br  "  " 
  4  3,7-dichloro-myrcene  C10H14Cl2  "  " 
  5  (Z)-10-bromo-3-
methoxy-α-myrcene 
C11H17OBr  "  " 
  6  (E)-10-bromo-3-
methoxy-α-myrcene 
C11H17OBr  "  " 
  7  3-bromo-7-chloro-
myrcene 
C10H14BrCl  "  " Mar. Drugs 2011, 9                       
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  8  (Z)-10-bromo-1-
methoxy-myrcene 
C11H17OBr  "  " 
  9  (E)-10-bromo-1-
methoxy-myrcene 
C11H17OBr  "  " 
[48]    (−)-3-bromomethyl-3-
chloro-7-methyl-1,6-
octadiene 
C10H16BrCl  "  Trincomalee 
(Foul Point) Sri 
Lanka 
[49]    2-(1-chloro-2-
hydroxyethyl)-4,4-
dimethylcyclohexa-2, 
5-dienone: a precursor 
of 4,5-dimethylbenzo 
[b] furan 
-  -  - 
[20]  1  (2Z,6E)-1,8-dichloro-3-
chloromethyl-7-
methylocta-2,6-diene  
C10H15Cl3  acyclic 
halogenated 
monoterpene 
Rib Reef, Great 
Barrier Reef, 
Australia 
  2  (E)-1,2-dibromo-3-
chloromethylene-7-
methyloct-6-ene 
C10H15Br2Cl  "  " 
  3  (Z)-1-chloro-3-
chloromethyl-7-
methylocta-2,6-diene 
C10H16Cl2  "  " 
  4  (Z)-1,6-dichloro-3-
chloromethyl-7-
methylocta-2,7-diene 
C10H15Cl3  "  " 
  5  (2R*,3(8)E,4S*,6R*)-6-
bromo-2-chloro-1,4-
oxido-3,(8)-ochtodene 
C10H14BrClO  epimeric bicyclic 
monoterpene 
" 
  6  (2S*,3(8)E,4S*,6R*)-6-
bromo-2-chloro-1,4-
oxido-3,(8)-ochtodene 
C10H14BrClO  "  " 
[50]    (Z)-3-bromo-8-chloro-
6-chloromethyl-2-
methylocta-1,6-diene 
(9,6-hydroxymethyl-2-
methylocta-2,8-dien-6-
ol  
-  -  - 
[21]  1  (2Z)-6-bromo-3-
chloromethyl-1,7-
dichloro-7-methylocta-
2-ene 
C10H16Cl3Br  acyclic 
halogenated 
monoterpene 
Nelly Bay, 
Magnetic Island, 
Queensland, 
Australia 
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  2  (2Z,6E)-3-
chloromethyl-1-
chloroocta-2,6-dien-8-
al 
C10H14 OCl2  "  " 
  3  3-methoxymethyl-6-
methoxyl-7-
methylocta-1,7(10)-
dien-3-ol 
C12H22 O3  "  " 
  4  (2Z,6S)-3-
chloromethyl-1-
methylocta-2,7(10)-
dien-6-ol 
C11H19 O2Cl  "  " 
  5  (2Z,6S)-3-
chloromethyl-6-
methylocta-2,7(10)-
dien-1-ol 
C11H19 O2Cl  "  " 
[22]  1  halomon/6(R)-bromo-
3(S)-(bromomethyl)-7-
methyl-2,3,7-trichloro-
1-octene 
C10H15Br2Cl3  acyclic 
halogenated 
monoterpene 
Chanaryan, Batan 
Is., Batanes, 
Philippines 
  2  -  C10H13Cl  cyclic halogenated 
monoterpene 
Banilad, Bacong, 
Negros Oriental, 
Philippines 
[23]  2  isohalomon  C10H15Br2Cl3  acyclic 
halogenated 
monoterpene; 
isomeric with 
halomon 
Chanaryan, Batan 
Is., Batanes, 
Philippines 
  3  -  C10H14BrCl3  acyclic 
halogenated 
monoterpene 
" 
  4  -  C10H14Br2Cl2  "  " 
  5  -  C10H14Br3Cl  cyclic halogenated 
monoterpene 
" 
  6  -  C10H14BrCl3  "  " 
  7  -  C10H13Cl3  "  " 
  8  -  C10H15BrCl2  acyclic 
halogenated 
monoterpene 
" 
  9  -  C10H16Br2Cl2  "  " 
  10  -  C10H16BrCl  "  Halona Blowhole 
Is, Oahu, Hawaii 
  11  -  C10H15BrCl  "  " 
  12  -  C10H14BrCl  cyclic halogenated 
monoterpene 
" Mar. Drugs 2011, 9                       
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[8]  1  apakaochtodene A/ 
6(S*)-bromo-
1,4(S*),8(R*)-trichloro-
2(Z)-ochtodene 
C10H14Cl3Br  cyclic halogenated 
monoterpene 
Apaka Point 
Beach, Guam 
  2  apakaochtodene B/ 
6(S)-bromo-1,4(S), 
8(R*)-trichloro-2(E)-
ochtodene 
C10H14Cl3Br  cyclic halogenated 
monoterpene 
Gun Beach; 
Double Reef; 
Pago Bay; Guam 
[11]  1  myrcene/7-methyl-3-
methylene-1,6-
octadiene 
C10 H16O  acyclic non-
halogenated 
monoterpene 
microplantlet 
culture, Double 
Reef NW Guam 
  2  10E-bromomyrcene/ 
E-3-bromomethylene-
7-methyl-1,6-octadiene 
C10H15Br   "  " 
  3  10Z-bromomyrcene/ 
Z-3-bromomethylene-
7-methyl-1,6-octadiene 
C10H15Br   "  " 
  4  10E-bromo-3-chloro-
α-myrcene/E-3-
bromomethylene-6-
chloro-1,7-octadiene 
C10H14BrCl  "  " 
  5  -  C10H14Br2  "  " 
  6  apakaochtodene B/ 
6(S)-bromo-1,4(S), 
8(R*)-trichloro-2(E)-
ochtodene 
C10H14BrCl3  cyclic halogenated 
monoterpene 
" 
  7  -  C10 H16O  non-halogenated 
monoterpene 
" 
  8  bromomyrcene isomer  C10H15Br   halogenated 
monoterpene 
" 
  9  7-chloromyrcene/2-
chloro-3-methylene-7-
methyl-1,6-octadiene 
C10H15Cl  "  " 
  10    C10H14Cl  "  " 
  11  chloromyrcene 
derivative 
C10H16Cl  "  " 
  12  bromomyrcene isomer  C10H15Br   "  " 
  13  chloromyrcene 
derivative 
C10H14Cl  "  " 
  14  -  C10H18Cl2  "  " 
  15  -  C15H18 O4  sesquiterpene  " 
[13]  5  1,2-dibromoochtoda-
3(8),5-dien-4-one 
C22H12Br2O  cyclic halogenated 
monoterpene 
Cape Zampa, 
Okinawa, Japan 
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  6  1-bromo-2-
chloroochtoda-3(8),5-
dien-4-one 
C10H12BrClO  "  " 
  7  1,2-dichloroochtoda-
3(8),5-dien-4-one 
C10H12Cl2O  "  Gushichan coast, 
Okinawa, Japan 
  8  (1Z)-1-bromoochtoda-
1,3(8),5-trien-4-one 
C10H11BrO  "  Cape Zampa, 
Okinawa, Japan 
  9  (1Z)-1-chloroochtoda-
1,3(8),5-trien-4-one 
C10H11ClO  "  " 
[12]  1  halomon/6(R)-bromo-
3(S)-(bromomethyl)-7-
methyl-2,3,7-trichloro-
1-octene 
C10H15Br2Cl3  acyclic 
halogenated 
monoterpene 
Tolagniaro, Fort 
Dauphin, 
Madagascar 
  2  -  C10H13ClBr  "  " 
  3  -  C10H14Cl2Br    "  " 
  4     C10H15Br2Cl3  "  " 
Table  S2.  Compound peaks detected from GC-MS analysis of samples used for 
characterization of the life history stages of P. hornemannii. Identifications based on 
comparison of either Kovat’s Indices (KI) of compounds retrieved from the Retention 
Index Calculator [37] or mass spectral comparison of compounds retrieved from NIST or 
MassBase. Asterisk (*) indicates compounds with parent ions showing halogenated mass 
spectral patterns. 
#  Sample  Base 
Peak 
  KI  KI Based ID   Mass Spectra Based ID 
      RT (min)    Nearest 
KI 
Lucero et al. [37]  NIST  MassBase 
1  F6_2  93  6.1863  994  993/994  beta-myrcene/6-
methyl-5-hepten-2-ol 
b-myrcene  b-myrcene 
2  T1_1  104  6.5874  1008  1007  α-phellandrene  -  - 
3  T1_2  104  6.5909  1008  1007  α-phellandrene  -  - 
4  M1_1  91  6.7685  1016  1017  α-terpinene  Benzene,  
tert-butyl- 
4-
methylacetophenone 
5  F3_3  79  6.9501  1023  1024  r-cymene  -  - 
6  M1_2  79  6.9532  1023  1024  r-cymene  -  - 
7  M1_3  91  7.017  1026  1025  p-cymene  carbonic acid  1-phenylpropan-2-
one 
8  M2_2  91  7.021  1026  1025  p-cymene  -  protopine 
9  F3_2  91  7.0387  1027  1025  p-cymene  -  N-Methyl-N-
propagylbenzylamine 
10  T2_1  57  8.0381  1063  1062  y-terpinene  -  - 
11  M2_2  132  8.8894  1089  1089  p-mentha-
2,4(8)diene 
-  - Mar. Drugs 2011, 9                       
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12  T2_1  117  9.5127  1110  1099  linalool  -  - 
13  F4_3  117  9.8874  1124  1123  chrysanthenone  -  - 
14  M1_3  117  9.9855  1128  1127  α-campholenal  -  - 
15  M2_2  91  10.2042  1136  1127  α-campholenal  -  - 
16  F2_2  91  10.2132  1136  1127  α-campholenal  -  Dimethirimol 
17  T2_1  119  10.4565  1145  1145  camphor  -  Benzimidazole 
18  M1_1  68  10.8826  1160  1158  isobomeol  -  - 
19  F7_3  68  10.8845  1160  1158  isobomeol  -  - 
20  T2_1  68  10.8866  1160  1158  isobomeol  -  - 
21  F3_3  68  10.8873  1160  1158  isobomeol  -  - 
 
22  F4_1  117  11.3242  1174  1171  ethyl-benzoate  -  - 
23  F4_1  50  11.5177  1180  1180  m-cymen-8-ol  -  - 
24  T2_2  127  11.5317  1180  1180  m-cymen-8-ol  -  - 
25  T2_3  134  11.7619  1188  1187  p-cymen-8-ol  -  - 
26  M2_2  105  12.0654  1197  1196  methylchavicol  -  3-cyanopyridine 
27  F3_2  57  12.1827  1200  1203  n-decanal   3-Hexanone  - 
28  F7_3  113  12.3674  1207  1207  verbenone  -  - 
29  M1_2  113  12.3831  1208  1207  verbenone  -  - 
30  T1_3  91  12.3874  1208  1207  verbenone  -  - 
31  M2_2  93  12.6294  1217  1217  trans-carveol  -  - 
32  M1_2  69  12.7588  1222  1219  trans-carveol  -  - 
33  M1_1  55  12.8397  1225  1229  nerol  -  - 
34  F7_3  67  13.1203  1236  1236  thymol methyl ether  -  - 
35  M1_1  79  13.1266  1236  1236  thymol methyl ether  -  - 
36  F5_2  93  13.127  1236  1236  thymol methyl ether  -  Beta-pinene;  
y-eudesmol 
37  M2_2  93  13.32  1243  1243  carvone  -  - 
38  T1_1  93  13.327  1243  1243  carvone  2-
chloropropionyl 
chloride 
- 
39  T2_1  93  13.3305  1243  1243  carvone  -  - 
40 
*(Br) 
F6_2  69  13.6916  1256  1256  geraniol  -  - 
41  M1_1  91  13.6953  1256  1256  geraniol    - 
42  F2_1  69  13.6967  1256  1256  geraniol  -   
43  F5_1  69  13.6975  1256  1256  geraniol  -  - 
44  M2_1  91  13.9837  1266  1263  (E)-2-decenal  -  N-Methyl-N-
propagylbenzylamin
e 
45  F7_3  119  14.131  1271  1271  geranial  -  - 
46  F2_3  119  14.1354  1271  1271  geranial  -  - 
47  F3_2  69  14.4252  1281  1282  a-terpinen-7-al  -  - 
48  M2_3  69  14.4368  1281  1282  a-terpinen-7-al  -  - 
49  F5_1  91  14.6745  1289  1289  p-cymen-7-ol  -  - Mar. Drugs 2011, 9                       
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50  T2_1  91  14.68  1289  1289  p-cymen-7-ol  -  - 
51  F6_3  149  14.9157  1297  1297  perilla alcohol  -  Benzoylcholine 
52 * 
(Cl) 
F6_3  131  15.0641  1302  1302  trans-ascaridole  -  2-chloro-1-phenyl-
2-butene 
53  F6_1  166  15.3344  1313  1313  2E,4E-decadienal  -  2-chloro-1-phenyl-
2-butene 
54  F6_3  81  15.5368  1320  1313  2E,4E-decadienal  -  - 
55  M2_2  81  15.5381  1321  1313  2E,4E-decadienal  -  - 
56  T1_2  81  15.5481  1321  1313  2E,4E-decadienal  -  - 
57  M2_2  67  15.6269  1324  1313  2E,4E-decadienal  -  1-Adamantanamine 
58  M1_2  67  15.6354  1324  1313  2E,4E-decadienal  -  - 
59  F3_1  57  15.7447  1329  1339  d-elemene  -  - 
60  F2_1  57  15.7649  1329  1339  d-elemene  -  - 
61  M2_2  91  15.8827  1334  1339  d-elemene  -  - 
62  M1_2  91  15.8885  1334  1339  d-elemene  -  - 
63  M2_2  139  16.5157  1357  1357  eugenol  -  - 
64  F6_1  115  16.5278  1358  1357  eugenol  -  - 
65  M2_3  166  16.5392  1358  1357  eugenol  -  - 
66  M2_2  91  17.02  1375  1373  a-ylangene  -  - 
67  M2_3  91  17.0254  1376  1373  a-ylangene  -  - 
68  M1_2  91  17.0311  1376  1373  a-ylangene  -  - 
69  T2_1  127  17.403  1389  1389  isolongifolene  -  Imidazole-4-acetate 
70  T2_1  57  17.7476  1400  1399  1,7-di-epi-a-cedrene  -  - 
71  M2_2  79  17.7625  1401  1402  methyleugenol  -  - 
72  M2_3  127  17.7782  1402  1402  methyleugenol  -  - 
73  T2_2  67  18.1041  1415  1415  cis-a-bergarnotene  -  - 
74  T1_3  79  18.18  1418  1419  β-caryophyllene  -  - 
75  F6_1  79  18.1866  1419  1419  β-caryophyllene  -  - 
76  T1_1  79  18.1928  1419  1419  β-caryophyllene  Pyridine  - 
77  F5_1  79  18.1934  1419  1419  β-caryophyllene  -  camphene 
78  M1_2  79  18.1939  1419  1419  β-caryophyllene  -  - 
79 * 
(Br) 
F7_2  212  18.3193  1424  1420  β-caroyophyllene  -  - 
80  F6_2  210  18.4564  1429  1420  β-caroyophyllene  -  - 
81  M2_3  131  18.4673  1430  1420  β-caroyophyllene  -  - 
82  M1_1  67  18.5462  1433  1435  trans-a-bergamotene  -  - 
83  M1_2  67  18.5503  1433  1435  trans-a-bergamotene  -  - 
84  F2_2  133  18.6084  1435  1435  trans-a-bergamotene  -  - 
85  T2_2  69  18.6925  1439  1438  trans-a-bergamotene  -  - 
86  F3_3  69  18.6982  1439  1440  a-guaiene  -  - 
87  M2_3  69  18.7018  1439  1440  a-guaiene  -  - 
88  M1_1  91  18.7475  1441  1440  a-guaiene  -  - 
89  F4_2  69  18.8243  1444  1440  a-guaiene  -  - Mar. Drugs 2011, 9                       
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90  F7_2  69  18.8273  1444  1440  a-guaiene  -  - 
91  T1_3  69  18.8306  1444  1440  a-guaiene  -  - 
92  F2_2  210  19.1226  1456  1455  a-humulene  -  - 
93  F3_3  133  19.3339  1464  1464  a-acoradiene  -   
94  T2_2  105  19.4843  1469  1469  drima-7,9(11)-diene  -  - 
95  T2_1  105  19.4852  1469  1469  drima-7,9(11)-diene  -  - 
96  F7_2  131  19.4915  1470  1469  drima-7,9(11)-diene  -  - 
97  F5_1  91  19.6255  1475  1474  b-cadinene  -  - 
98  F6_3  91  19.7468  1479  1479  y-curcurnene  -   
99  F2_1  91  19.7581  1480  1480  germacrene D  -  - 
100  F4_1  153  20.0567  1491  1491  cis-β-guaiene  -  - 
101  F4_1  153  20.0567  1491  1491  cis-β-guaiene  -  - 
102  F3_2  71  20.2111  1496  1495  a-zingiberene  -   
103  F7_2  135  20.3621  1502  1499  a-muurolene  -  - 
104  F5_1  91  20.3727  1503  1506  d-selinene  -  - 
105  T2_1  91  20.3766  1503  1506  d-selinene  -  - 
106  F2_2  91  20.3829  1503  1506  d-selinene  --  - 
107  F6_1  205  20.6221  1513  1513  g-cadinene  -  - 
108  F4_3  205  20.6237  1513  1513  g-cadinene  -  - 
109  F7_2  205  20.6252  1513  1513  g-cadinene  -  5-bromo-4-
methoxyoct-1-ene 
110  T2_1  205  20.6278  1513  1513  g-cadinene  p-Benzoquinone  - 
111  F3_2  133  20.6781  1516  1514  sesquicineole  -  - 
112  F3_3  133  20.6803  1516  1514  sesquicineole  -  - 
113  F6_3  133  20.685  1516  1514  sesquicineole  -  - 
114  F5_1  69  20.8293  1522  1523  d-cadinene  -  -- 
115  F5_1  69  20.9154  1526  1525  eugenyl acetate  -  - 
116  F6_3  69  20.9158  1526  1525  eugenyl acetate  -  - 
117  F7_2  121  20.9204  1526  1525  eugenyl acetate  -  - 
118  T1_3  69  20.9227  1526  1525  eugenyl acetate  -  - 
119  F7_2  167  21.1103  1534  1533  cadina-1,4-diene1  -  - 
120  T2_2  91  21.1498  1536  1538  a-cadinene  -  - 
121  F6_1  167  21.43  1547  1548  elemol  -  - 
122  F7_2  167  21.4346  1547  1548  elemol  -  - 
123  T1_3  69  21.467  1549  1549  elemol  -  -- 
124  F3_2  69  21.4709  1549  1549  elemol  -  - 
125  F7_2  91  21.598  1554  1552  elemicin  -  - 
126  F6_2  91  21.6852  1557  1557  germacrene B  -  - 
127  F5_1  91  21.6859  1558  1557  germacrene B  -  - 
128  F6_3  91  21.6869  1558  1557  germacrene B  -  - 
129  M1_1  91  21.6895  1558  1557  germacrene B  -  - 
130  F6_3  67  21.7268  1559  1557  germacrene B  -  - 
131  F7_2  133  21.8253  1563  1564  β-calacorene  -  L-Asparagine 
132  T1_1  91  21.8405  1564  1564  β-calacorene  -  - 
133  F7_2  167  22.0012  1570  1574  prenopsan-8-ol  -  - Mar. Drugs 2011, 9                       
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134  T1_3  213  22.018  1571  1574  prenopsan-8-ol  -  - 
135  F6_3  132  22.0226  1571  1574  prenopsan-8-ol  -  - 
136  F6_3  153  22.0226  1571  1574  prenopsan-8-ol  -  - 
137  M1_1  91  22.3956  1586  1585  gleenol  -  - 
138  F2_2  133  22.5362  1591  1590  viridflorol  -  - 
139  F6_3  71  22.7179  1598  1590  viridflorol  -  - 
140  F3_2  71  22.7193  1598  1590  viridflorol  -  - 
141  F2_3  135  22.722  1598  1590  viridflorol  -  - 
142  F3_3  57  22.7547  1600  1607  b-oplopenone  -  - 
143  F3_2  57  22.7603  1600  1607  b-oplopenone  -  - 
144  F3_3  57  22.761  1600  1607  b-oplopenone  -  - 
145  F6_3  67  22.8782  1605  1607  b-oplopenone  -  - 
146  T2_2  68  23.0541  1613  1612  tetradecanal  -  - 
147  F4_3  148  23.2435  1622  1623  silphiperfol-6-en-5-
one 
-  - 
148  F3_1  135  23.2485  1622  1623  silphiperfol-6-en-5-
one 
-  - 
149  F5_3  91  23.52  1634  1633  y-eudesmol  -  - 
150  F4_3  91  23.5226  1634  1633  y-eudesmol  -  - 
151  F7_2  68  23.5261  1634  1633  y-eudesmol  -  - 
152  F7_2  68  23.5261  1634  1633  y-eudesmol  -  -- 
153  T2_2  68  23.5278  1634  1633  y-eudesmol  -  - 
154  F6_1  167  23.5309  1634  1633  y-eudesmol  -   
155  F6_2  67  23.7239  1643  1642  cubenol  -  allylcy-anide 
156  T1_3  91  23.8325  1647  1646  a-muurolol  -  - 
157  F7_2  132  23.8759  1649  1646  a-muurolol  -  - 
158  F7_2  132  23.9988  1654  1653  a-cadinol  -  - 
159  F6_2  149  24.3377  1669  1668  bulnesol  -  - 
160  F7_2  149  24.3428  1669  1668  bulnesol  -  - 
161  F6_3  167  24.6091  1680  1682  a-bisabolol  -  - 
162  F6_1  57   24.6252  1681  1682  a-bisabolol  -  - 
163  F7_2  69   24.8113  1689  1686  8-cedren-13-ol  -  - 
164  F7_2  69   24.8207  1689  1686  8-cedren-13-ol  -  - 
165  F2_3  67   24.9282  1693  1686  8-cedren-13-ol  -  - 
166  F6_1  57   25.0854  1700  1686  8-cedren-13-ol  -  Heptadecane 
167  F7_2  91   25.3006  1710  1686  8-cedren-13-ol  -  - 
168  F3_2  71   25.3224  1711  1735  oplopanone  -  - 
169  F3_3  68   25.4814  1718  1735  oplopanone  -  - 
170  F6_3  67   25.7278  1730  1735  oplopanone  -  - 
171  F7_2  103  25.7292  1730  1735  oplopanone  -  - 
172  F2_1  67   25.7318  1730  1735  oplopanone  -  - 
173  F2_3  133  25.8305  1735  1735  oplopanone  -  - 
174  F3_1  117  25.8366  1735  1735  oplopanone  -  - 
175  F7_2  167  26.3223  1757  1761  benzyl-benzoate  -  - 
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176  T2_1  167  26.5838  1769  1761  benzyl-benzoate  -  6-Methylmer-
captopurine 
177  F6_2  117  26.7333  1775  1789  8-a-acetoxyelemol  -  - 
178  T2_2  103  26.8111  1779  1789  8-a-acetoxyelemol  -  - 
179  F3_1  67   26.8577  1781  1789  8-a-acetoxyelemol  -  - 
180  F6_1  67   26.8599  1781  1789  8-a-acetoxyelemol  -  - 
181  F3_2  67   26.8671  1781  1789  8-a-acetoxyelemol  -  - 
182  T2_1  67   26.8697  1781  1789  8-a-acetoxyelemol  -  - 
183 * 
(Cl2) 
F6_1  103  26.8838  1782  1789  8-a-acetoxyelemol  -  - 
184  F3_1  103  26.8852  1782  1789  8-a-acetoxyelemol  -  - 
185 * 
(Br) 
F6_1  67   27.4286  1806  1798  nootkatone  -  - 
186 * 
(Br) 
F7_2  67   27.4342  1806  1798  nootkatone  -  - 
187  F2_1  67   27.4383  1807  1798  nootkatone  -  - 
188  F6_3  103  27.4961  1810  1798  nootkatone  -  - 
189  F6_1  67   27.5012  1810  1798  nootkatone  -  - 
190  F6_2  67   27.5676  1813  1827  isopropyl 
tetradecanoate 
-  - 
191  F6_2  69   28.0351  1836  1827  isopropyl 
tetradecanoate 
-  - 
192  F3_2  69   28.0387  1836  1827  isopropyl 
tetradecanoate 
-  - 
193  F6_1  91   28.3153  1849  1867  flourensiadiol  -  - 
194  F3_2  149  28.735  1869  1867  flourensiadiol  -  - 
195 * 
(ClBr) 
F6_2  69   29.2918  1895  1878  hexadecanol  -  - 
196  F5_3  67   29.4766  1903  1927  methyl 
hexadecanoate 
-  - 
197  T2_1  67   29.4889  1904  1927  methyl 
hexadecanoate 
-  - 
198  F7_2  91   30.7705  1968  1999  eicosane  -  - 
199  T2_2  91   30.7753  1969  1999  eicosane  -  - 
200  F3_2  91   30.7855  1969  1999  eicosane  -  - 
201  T2_2  64   31.6475  -  -  -  -  - 
202  T2_2  129  38.661   -   -   -  -  - 
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Table S3. Compound peaks detected from GC-MS analysis of samples for evaluation of 
non-polar secondary metabolite patterns of 5 cryptic species of P. hornemanni found in 
Batanes, Philippines. Identifications based on comparison of either Kovat’s Indices (KI) of 
compounds retrieved from the Retention Index Calculator [37] or mass spectral 
comparison of compounds retrieved from NIST or MassBase. Asterisk (*) indicates 
compounds with parent ions showing halogenated mass spectral patterns. 
#  Sample  Base 
Peak 
   KI  KI Based ID   Mass Spectra Based ID 
      RT 
(min) 
  Nearest 
KI 
Lucero et al. [37]  NIST  Massbase 
1  B4B  57  8.1122  1065  1062  y-terpinene  -  - 
2  B4C  69  8.7386  1085  1085  artemisia-alcohol  -  - 
3  B4C  57  9.1807  1098  1097  linalool  -  - 
4  B4B  71  9.1841  1098  1097  linalool  -  - 
5  B6C  57  9.4047  1106  1099  linalool  3-hexanone, 
2,2-dimethyl- 
2-methylbutane 
6  B4C  69  11.2515  1172  1171  ethyl-benzoate  -  - 
7-  * 
(Cl) 
B3A  69  11.2560  1172  1171  ethyl-benzoate  -  - 
8  B4A  57  14.3547  1279  1277  trans-carvone-
oxide 
-  2,2-dimethylbutane 
9  B4B  57  14.3593  1279  1277  trans-carvone-
oxide 
-  3-ethylhexane 
10  B3B  57  14.5560  1285  1286  borneol-acetate  -   
11  B3A  69  15.2678  1310  1306  undecanal  -  trans-4-octene 
12  B3A  57  15.6497  1325  1314  2E,4E-decadienal  -   
13  B6B  57  15.6518  1325  1314  2E,4E-decadienal  -   
14  B4A  71  16.5884  1360  1357  eugenol  -  2-methylpentane 
15  B6C  57  17.8154  1403  1403  italicene  -  2,2-dimethylbutane 
16  B3A  57  17.8289  1404  1403  italicene  -   
17  B10  71  20.306  1500  1499  a-muurolene  -  Pentacosane 
18  B3A  57  20.4025  1504  1506  d-selinene  -  tripropylamine 
19  B4A  191  20.715  1517  1514  sesquicineole  -   
20  B6C  57  21.0008  1529  1532  cadina-1,4-diene  -   
21- * 
(Br) 
B3B  57  21.0024  1529  1532  cadina-1,4-diene  -  1-octene 
22  B4A  69  21.5566  1552  1552  elemicin  -   
23  B4A  57  25.1819  1704  1686  8-cedren-13-ol  -   
24  B4B  71  25.4142  1715  1735  oplopanone  -  Hexacosane 
25  B4B  69  26.0498  1745  1747  6S-7R-bisabolone  -  10-methyl-1-
dodecanol 
26  B4A  57  27.4031  1805  1798  nootkatone  -  4-methyl-1-pentene 
27  B3B  57  27.9515  1832  1827  isopropyl-
tetradecanoate 
-  2,4-dimethylpentane 
28  B3B  71  29.9932  1930  1927  methyl-
hexadecanoate 
-  docosane Mar. Drugs 2011, 9                       
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29  B6B  57  30.4182  1951  1927  methyl-
hexadecanoate 
-  - 
30  B10  69  30.5987  1960  1927  methyl-
hexadecanoate 
-  - 
31  B4C  73  30.6949  1965  1999  eicosane  -  - 
32  B6B  71  32.0267    -  -  3-hexanone, 
2,2-dimethyl- 
2,2-dimethylbutane 
33  B3B  71  32.0458    -  -  -  2,2-dimethylbutane 
34  B6B  69  34.1452    -  -  -  docosane 
35  B3B  69  34.7128    -  -  -  - 
36  B4C  69  34.7233    -  -  -  - 
37  B6C  71  35.0713    -  -  -  - 
38  B3C  71  36.7162    -  -  -  3-ethylpentane 
39  B9B  395  38.2697    -  -  -  - 
40  B6C  71  38.8875    -  -  -  3-ethylhexane 
41  B6B  71  39.0147    -  -  -  - 
42  B4C  57  39.4792    -  -  -  3-ethylhexane 
43  B6B  57  39.4822    -  -  -  3,3-dimethyl-1-
butene 
44  B4C  71  39.6266    -  -  -  3-ethylpentane 
45  B3C  71  39.7884    -  -  -  - 
46  B6B  57  40.4997    -  -  3-hexanone, 
2,2-dimethyl- 
2-methylbutane 
47  B6C  57  40.7684    -  -  -  3-ethylpentane 
48  B3C  71  40.7722    -  -  -  - 
49  B4C  57  43.09    -  -  -  3-ethylpentane 
50  B6B  57  43.0982    -  -  -  2,2,4,6,6-
pentamethylheptane 
51  B6C  85  43.2865    -  -  -  2-methylnonane 
52  B6B  71  43.3628    -  -  -  3-ethylpentane 
53  B3C  71  43.3691    -  -  -  - 
54  B3B  85  43.7727    -  -  -  3,3-dimethyl-1-
butene 
55  B4B  85  44.3901    -  -  -  Amitrole 
56  B6B  71  44.3953    -  -  -  3-aminopropiononitrile 
57  B4A  71  46.2638    -  -  -  - 
58  B3C  71  46.8143    -  -  -  2,3-dimethylbutane 
59  B6B  71  46.822    -  -  3-hexanone, 
2,2-dimethyl- 
- 
60  B6C  71  47.3544    -  -  -  - 
61  B4A  71  47.7467    -  -  -  3-ethylypentane 
62  B3A  57  47.7529    -  -  -  3,3-dimethyl-1-
butene 
63  B4A  71  48.0072    -  -  -  - 
64  B6B  71  48.0159    -  -  -  - Mar. Drugs 2011, 9                       
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65  B6C  71  48.0169    -  -  -  - 
66  B4A  71  48.0321    -  -  -  - 
67  B4B  71  50.7731    -  -  -  - 
Table S4. Compound peaks detected from GC-MS analysis of samples used for evaluation 
of temporal and spatial patterns of non-polar metabolites of three cryptic species of P. 
hornemanni found in the Visayas. Identifications based on comparison of either Kovat’s 
Indices (KI) of compounds retrieved from the Retention Index Calculator [37] or mass 
spectral comparison of compounds retrieved from NIST or MassBase. Asterisk (*) 
indicates compounds with parent ions showing halogenated mass spectral patterns. 
#  Sample 
Base 
Peak 
   KI  KI Based ID   Mass Spectra Based ID 
     
RT 
 
Nearest KI  Lucero et al. [37]  Massbase 
1  3A  57  8.1118  1065  1062  y-terpinene  undecane 
2  15A  57  14.556  1285  1286  borneol acetate  1-nonene 
3  9A  57  14.556  1285  1286  borneol acetate  pentacosane 
4  29A  57  20.3128  1500  1499  a-muurolene  tricosane 
5  15B  71  20.5458  1510  1509  β-bisabolene  3-ethylpentane 
6  15A  57  25.186  1705  1686  8-cedren-13-ol  - 
7  34A  57  25.4206  1716  1735  oplopanone  - 
8  15B  71  26.6674  1772  1761  benzyl-benzoate  2-methylbutane 
9  15A  57  27.8534  1827  1827  isopropyl tetradecanoate 
  10  44BB  71  30.0015  1930  1927  methyl hexadecanoate  docosane 
11  8B  57  30.4069  1950  1927  methyl hexadecanoate 
  12  15B  71  31.6111  -  -  -  - 
13  15A  57  31.8326  -  -  -  - 
14  15B  57  31.8342  -  -  -  1,4-dimethylhexane 
15  44BA  71  34.1535  -  -  -  docosane 
16  15B  71  34.2967  -  -  -  3-ethylpentane 
17  15A  57  34.76  -  -  -  1-octene 
18  15A  71  35.4496  -  -  -  2-methylbutane 
19  15B  57  35.5757  -  -  -  - 
20  15B  57  35.5757  -  -  -  2,2-dimethylbutane 
21  44BA  71  37.9407  -  -  -  docosane 
22  15B  410  38.2743  -  -  -  - 
23  15A  71  39.3484  -  -  -  3-ethylhexane 
24  15A  71  40.0877  -  -  -  2,2-dimethylbutane 
25  15A  71  40.0981  -  -  -  beta-Aminopropionitrile 
26  15B  71  42.5358  -  -  -  2-methylbutane 
27  15B  57  43.9626  -  -  -  4-methyloctane 
28  44C  71  44.6454  -  -  -  - 
29  15A  57  45.2255  -  -  -  2,2-dimethylbutane 
30  15A  71  47.3529  -  -  -  - 
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31  15B  57  47.3534  -  -  -  - 
32  15B  57  47.3581  -  -  -  2,4-dimethylpentane 
33  15A  71  47.6237  -    -   -  2,4-dimethylhexane 
Figure S1. Map of sampling sites. (a)  Map of the Philippines indicating location of 
Batanes and Visayas;  (b)  Sampling sites in Batan and Sabtang Islands in Batanes;  
(c) Sampling sites in Siquijor, Negros, and Cebu Islands in the Visayas). 
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